Table 3. Characteristics of male... | American Society of Hematology

Table 3.

Characteristics of male patients

Patient no.	Age, y	Disease duration, mo	Previous therapy for CML	Phase at imatinib start	Imatinib therapy, mo	Ph⁺, %	Karyotype
34	50	18	IFN, Ara-C, Ida	CP1	11	0	46XY[4]/46,XY,t(3;21)(q27?;q22)[15]
35	41	1	HU	CP 1, initial	11	0	46XY[18]
36	63	1	None	CP 1, initial	6	0	46XY[20]
37	48	2	HU	CP1, initial	16	0	46XY[20]
38	59	27	IFN, HU	CP1	12	0	46XY[20]
39	61	36	HU, IFN, Ara-C, Ida, Bu, ABMT	CP1	6	0	46XY[20]
40	50	48	HU, IFN, Ara-C, Ida, Bu, ABMT	CP1	11	0	46XY[20]
41	66	4	None	CP 1, initial	8	0	46XY[20]
42	36	6	HU	CP 1, initial	16	0	46XY[20]
43	46	3	HU	CP 1, initial	6	0	46XY[20]
44	72	45	HU	CP1	22	0	46XY[20]
45	39	31	HU, IFN, Ara-C, Ida, Bu, ABMT	CP2	21	0	46XY[20]
46	49	18	HU, IFN, Ara-C	AP	8	0	46XY[20]
47	47	69	HU, IFN, Ara-C, Ida, Bu, ABMT	CP1	16	0	46,XY[13]/46,XY,del(20q)[9]
48	33	6	HU	CP 1, initial	16	5	46XY[19];46XY,t(9;22)[1]
49	73	32	HU, IFN, Bu, 6-mercaptopurine	CP1	8	10	46XY[18];46XY,t(9;22)[2]
50	41	55	HU, IFN	CP1	22	5	46XY[19];46XY,t(9;22)[1]
51	72	14	HU	AP	10	11	46,XY[6]/45,X-Y[2]/46,XY,t(9;22)[1]
52	55	35	IFN, HU	CP1	27	8	46,XY[14]/45,X-Y[9]/46,XY,t(9;22)[2]
53	37	58	HU, IFN, Ida, Ara-C, Bu, ABMT, 2 Gy TBI, fludarabine, MUD allograft	MCR	12	8	6,XY[18]/46,XY,t(7;17)(q11;q21)[5]/ 46,XY,t(9;22)[2]

Patient no.	Age, y	Disease duration, mo	Previous therapy for CML	Phase at imatinib start	Imatinib therapy, mo	Ph⁺, %	Karyotype
34	50	18	IFN, Ara-C, Ida	CP1	11	0	46XY[4]/46,XY,t(3;21)(q27?;q22)[15]
35	41	1	HU	CP 1, initial	11	0	46XY[18]
36	63	1	None	CP 1, initial	6	0	46XY[20]
37	48	2	HU	CP1, initial	16	0	46XY[20]
38	59	27	IFN, HU	CP1	12	0	46XY[20]
39	61	36	HU, IFN, Ara-C, Ida, Bu, ABMT	CP1	6	0	46XY[20]
40	50	48	HU, IFN, Ara-C, Ida, Bu, ABMT	CP1	11	0	46XY[20]
41	66	4	None	CP 1, initial	8	0	46XY[20]
42	36	6	HU	CP 1, initial	16	0	46XY[20]
43	46	3	HU	CP 1, initial	6	0	46XY[20]
44	72	45	HU	CP1	22	0	46XY[20]
45	39	31	HU, IFN, Ara-C, Ida, Bu, ABMT	CP2	21	0	46XY[20]
46	49	18	HU, IFN, Ara-C	AP	8	0	46XY[20]
47	47	69	HU, IFN, Ara-C, Ida, Bu, ABMT	CP1	16	0	46,XY[13]/46,XY,del(20q)[9]
48	33	6	HU	CP 1, initial	16	5	46XY[19];46XY,t(9;22)[1]
49	73	32	HU, IFN, Bu, 6-mercaptopurine	CP1	8	10	46XY[18];46XY,t(9;22)[2]
50	41	55	HU, IFN	CP1	22	5	46XY[19];46XY,t(9;22)[1]
51	72	14	HU	AP	10	11	46,XY[6]/45,X-Y[2]/46,XY,t(9;22)[1]
52	55	35	IFN, HU	CP1	27	8	46,XY[14]/45,X-Y[9]/46,XY,t(9;22)[2]
53	37	58	HU, IFN, Ida, Ara-C, Bu, ABMT, 2 Gy TBI, fludarabine, MUD allograft	MCR	12	8	6,XY[18]/46,XY,t(7;17)(q11;q21)[5]/ 46,XY,t(9;22)[2]

Patients 34, 47, 51, 52, and 53 had abnormalities in Ph⁻ cells; the karyotype reflects the most recent evaluation.

MUD indicates matched unrelated donor; and TBI, total body irradiation. Other abbreviations are explained in the text and Table 1.